Johnson & Johnson
Description
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
About
CEO
Mr. Joaquin Duato
Employees
131,900
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - General
MIC code
XNYS
Address
One Johnson & Johnson Plaza, New Brunswick, NJ 08933, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Jan 20, 2026 | — | — | — | — |
| Oct 13, 2025 | — | — | — | — |
| Jul 15, 2025 | — | — | — | — |
| Apr 14, 2025 | — | — | — | — |
Earnings estimate
|
Current Quarter
(Mar 2025)
|
Next Quarter
(Jun 2025)
|
Current Year
(Dec 2025)
|
Next Year
(Dec 2026)
|
|
|---|---|---|---|---|
| Number of analysts | 13 | 13 | 18 | 19 |
| Average estimate | 2.64 | 2.73 | 10.55 | 11.11 |
| Low estimate | 2.51 | 2.61 | 10.28 | 10.42 |
| High estimate | 2.88 | 2.95 | 10.66 | 11.73 |
| Last year EPS | 2.71 | 2.82 | 9.98 | 10.55 |
[stock_revenue_estimate]
Growth estimates
Current qtr (Mar 2025)
-2.570%
Next qtr. (Jun 2025)
-3.310%
Current year (Dec 2025)
5.680%
Next year (Dec 2026)
5.360%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B |
| Cost of revenue | 26.55B | 24.60B | 23.40B | 28.43B | 27.56B |
| Gross profit | 58.61B | 55.39B | 55.34B | 54.16B | 54.50B |
| Operating expense | |||||
| Research & development | 15.09B | 14.14B | 14.28B | 12.34B | 11.36B |
| Selling general and admin | 20.11B | 19.05B | 20.12B | 22.08B | 22.18B |
| Other operating expenses | — | — | — | — | — |
| Operating income | 23.41B | 22.21B | 20.94B | 19.73B | 20.97B |
| Non operating interest income | |||||
| Income | 1.26B | 490.00M | 53.00M | 111.00M | 357.00M |
| Expense | 772.00M | 276.00M | 183.00M | 201.00M | 318.00M |
| Other income expense | -8.80B | -3.06B | -1.64B | -3.15B | -3.68B |
| Pretax income | 15.06B | 19.36B | 19.18B | 16.50B | 17.33B |
| Tax provision | 1.74B | 2.99B | 1.38B | 1.78B | 2.21B |
| Net income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B |
| Basic EPS | 13.88 | 6.86 | 7.93 | 5.59 | 5.74 |
| Diluted EPS | 13.72 | 6.73 | 7.81 | 5.51 | 5.63 |
| Basic average shares | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B |
| Diluted average shares | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B |
| EBITDA | 32.32B | 30.16B | 27.86B | 24.18B | 25.81B |
| Net income from continuing op. | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 167.56B | 187.38B | 182.02B | 174.89B | 157.73B |
| Current assets | |||||
| Cash | 3.34B | 3.69B | — | — | — |
| Cash equivalents | 18.52B | 9.20B | — | — | — |
| Cash and cash equivalents | 21.86B | 12.89B | 14.49B | 13.99B | 17.31B |
| Other short term investments | 1.07B | 9.39B | 17.12B | 11.20B | 1.98B |
| Accounts receivable | 14.87B | 14.04B | 15.28B | 13.58B | 14.48B |
| Other receivables | 4.51B | 2.88B | 3.70B | — | — |
| Inventory | 11.18B | 10.27B | 10.39B | 9.34B | 9.02B |
| Prepaid assets | — | — | 3.70B | 3.13B | 2.39B |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | 5.83B | — | — | 94.00M |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | 3.70B | 3.13B | 2.39B |
| Non current assets | |||||
| Properties | — | — | — | — | — |
| Land and improvements | 795.00M | 784.00M | 884.00M | 882.00M | 854.00M |
| Machinery furniture equipment | 28.98B | 26.60B | 29.77B | 29.10B | 26.96B |
| Construction in progress | 5.63B | 4.68B | 4.14B | 4.32B | 3.64B |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -27.88B | -25.55B | -28.72B | -28.04B | -25.67B |
| Goodwill | 107.29B | 110.58B | 116.88B | 126.19B | 114.92B |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 34.18B | 38.49B | 46.39B | 53.40B | 47.64B |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 23.43B | 39.57B | 20.44B | 15.10B | 13.51B |
| Total liabilities | 98.78B | 110.57B | 108.00B | 111.62B | 98.26B |
| Current liabilities | |||||
| Accounts payable | 9.63B | 9.89B | 11.06B | 9.51B | 8.54B |
| Accrued expenses | 26.21B | 24.30B | 25.71B | 25.48B | 20.60B |
| Short term debt | 3.45B | 12.76B | 3.77B | 2.63B | 1.20B |
| Deferred revenue | — | — | — | — | — |
| Tax payable | 2.99B | 2.22B | 1.11B | 1.39B | 2.27B |
| Pensions | 3.99B | 3.05B | 3.59B | 3.48B | 3.35B |
| Other current liabilities | — | 3.59B | — | — | — |
| Non current liabilities | |||||
| Long term debt | 25.88B | 26.89B | 29.99B | 32.64B | 26.49B |
| Provision for risks and charges | 2.88B | 4.31B | 5.71B | 6.56B | 7.44B |
| Deferred liabilities | 3.19B | 3.99B | 7.49B | 7.21B | 5.96B |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 13.40B | 10.15B | 10.69B | 11.94B | 11.73B |
| Shareholders equity | |||||
| Common stock | 3.12B | 3.12B | 3.12B | 3.12B | 3.12B |
| Retained earnings | 153.84B | 128.35B | 123.06B | 113.89B | 110.66B |
| Other shareholders equity | -12.53B | -12.97B | -13.06B | -15.24B | -15.89B |
| Total shareholders equity | 68.77B | 76.80B | 74.02B | 63.28B | 59.47B |
| Additional paid in capital | 153.84B | 128.35B | 123.06B | 113.89B | 110.66B |
| Treasury stock | 75.66B | 41.69B | 39.10B | 38.49B | 38.42B |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||||||||
| Net Income | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B | 13.83B | 10.51B | 9.67B | 13.33B | 12.27B | 12.95B | 10.58B | 11.05B | 10.06B | 8.18B | 7.20B | 6.60B | 5.67B | 4.95B | 4.27B | 3.00B | 3.30B | 2.89B | 2.40B | 2.01B | 1.79B | 1.63B | 1.46B | 1.14B | 1.08B |
| Depreciation | 7.49B | 6.97B | 7.39B | 7.23B | 7.01B | 6.93B | 5.64B | 3.75B | 3.75B | 3.90B | 4.10B | 3.67B | 3.16B | 2.94B | 2.77B | 2.83B | 2.78B | 2.18B | 2.09B | 2.12B | 1.87B | 1.66B | 1.61B | 1.59B | 1.51B | 1.29B | 1.07B | 1.01B | 857.00M | 724.00M | 617.00M | 560.00M | 493.00M | 474.00M | 414.00M |
| Deferred Taxes | -4.19B | -1.66B | -2.08B | -1.14B | -2.48B | -1.02B | 2.41B | -341.00M | -270.00M | 441.00M | -607.00M | -39.00M | -836.00M | 356.00M | -436.00M | 22.00M | -1.76B | -1.17B | -235.00M | -676.00M | -720.00M | -74.00M | -106.00M | -128.00M | -26.00M | -297.00M | -121.00M | -3.00M | -63.00M | -66.00M | — | -8.00M | -22.00M | -46.00M | -8.00M |
| Stock-Based Compensation | 1.16B | 1.14B | 1.14B | 1.01B | 977.00M | 978.00M | 962.00M | 878.00M | 874.00M | 792.00M | 728.00M | 662.00M | 621.00M | 614.00M | 628.00M | 627.00M | 698.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 483.00M | — | — | -1.15B | — | — | — | — | — | — | — | 339.00M | 9.70B | 13.35B | 12.32B | 86.00M | 22.00M | 645.00M | 509.00M | 510.00M | — | — | — | — | — | — | — | — | — | — | -19.00M | — | — | — | — |
| Accounts Receivable | -624.00M | -1.29B | -2.40B | 774.00M | -289.00M | -1.19B | -633.00M | -1.07B | -433.00M | -247.00M | -632.00M | -9.00M | -915.00M | -207.00M | 453.00M | -736.00M | -416.00M | -699.00M | -568.00M | -111.00M | -691.00M | -510.00M | -258.00M | -468.00M | -630.00M | -163.00M | -318.00M | -306.00M | -265.00M | -239.00M | -310.00M | -211.00M | -244.00M | -127.00M | -179.00M |
| Accounts Payable | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | 785.00M | -3.82B | -4.27B | -3.23B | 94.00M | -2.76B | 9.15B | -1.36B | 1.78B | -1.77B | -2.02B | -3.82B | 4.70B | -1.17B | 1.34B | -717.00M | -1.00B | -69.00M | 1.45B | 905.00M | -176.00M | -1.10B | 350.00M | 806.00M | 544.00M | 195.00M | -48.00M | 59.00M | -167.00M | 88.00M | 96.00M | -170.00M | -169.00M | -147.00M | -17.00M |
| Operating Cash Flow | 40.25B | 19.28B | 20.65B | 18.21B | 20.43B | 18.24B | 18.83B | 18.40B | 21.10B | 19.43B | 15.41B | 11.31B | 26.11B | 29.21B | 29.34B | 15.06B | 10.90B | 11.94B | 13.31B | 10.93B | 7.48B | 6.57B | 7.26B | 6.76B | 5.67B | 4.02B | 3.88B | 3.65B | 2.77B | 2.51B | 2.17B | 1.80B | 1.52B | 1.30B | 1.29B |
| Investing Activities | |||||||||||||||||||||||||||||||||||
| Capital Expenditures | -4.54B | -4.01B | -3.65B | -3.35B | -3.50B | -3.67B | -3.28B | -3.23B | -3.46B | -3.71B | -3.60B | -2.93B | -2.89B | -2.38B | -2.21B | -3.07B | -2.94B | -2.23B | -2.82B | -2.21B | -1.93B | -1.94B | -1.57B | -1.52B | -1.77B | -1.44B | -1.32B | -1.34B | -791.00M | -605.00M | -909.00M | -1.01B | -730.00M | -768.00M | -679.00M |
| Net Intangibles | -470.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -17.65B | -60.00M | -7.32B | -5.81B | -899.00M | -35.15B | -4.51B | -954.00M | -2.13B | -835.00M | -4.49B | -2.80B | -1.27B | -2.47B | -1.21B | -1.39B | -18.02B | -987.00M | -580.00M | -2.81B | -478.00M | -225.00M | -151.00M | -271.00M | -3.82B | — | — | — | -1.93B | — | — | — | — | — |
| Purchase of Investments | -10.91B | -32.38B | -30.39B | -21.09B | -3.92B | -5.63B | -6.15B | -33.95B | -40.83B | -34.91B | -18.92B | -13.43B | -29.88B | -15.79B | -10.04B | -3.67B | -9.66B | -467.00M | -5.66B | -11.62B | -7.59B | -6.92B | -8.19B | -5.68B | -3.83B | -1.01B | -112.00M | -123.00M | -151.00M | -19.00M | -86.00M | — | -173.00M | — | -87.00M |
| Sale of Investments | 19.39B | 41.61B | 25.01B | 12.14B | 3.39B | 4.29B | 28.12B | 35.78B | 34.15B | 24.12B | 18.06B | 14.80B | 30.40B | 11.10B | 7.23B | 3.06B | 7.99B | 426.00M | 9.19B | 12.06B | 8.06B | 7.35B | 5.97B | 4.83B | 3.06B | 400.00M | — | — | — | — | — | — | — | 11.00M | — |
| Investing Cash Flow | 1.35B | -12.37B | -8.68B | -20.83B | -6.19B | -3.17B | -14.87B | -4.76B | -7.74B | -12.31B | -5.10B | -4.51B | -4.61B | -7.85B | -7.60B | -4.19B | -5.91B | -20.29B | -620.00M | -2.62B | -4.53B | -2.20B | -4.09B | -2.67B | -3.09B | -6.07B | -1.61B | -1.69B | -1.10B | -2.56B | -1.26B | -1.17B | -1.03B | -1.06B | -897.00M |
| Financing Activities | |||||||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | 2.00M | 5.00M | 7.43B | 3.00M | 5.00M | 8.99B | 12.00B | 75.00M | 2.10B | 3.61B | 45.00M | 4.47B | 1.12B | 9.00M | 1.64B | 5.10B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -24.52B | -8.68B | -2.99B | -3.73B | -2.92B | -4.03B | -3.11B | -4.24B | -1.11B | -3.11B | -2.99B | -6.98B | -11.22B | -6.60B | -7.01B | -7.34B | -21.71B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -1.60B | 65.00M | 395.00M | -627.00M | 575.00M | -148.00M | -188.00M | -15.00M | -57.00M | — | 56.00M | -83.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -100.00M | — |
| Financing Cash Flow | -39.89B | -16.75B | -16.27B | -9.90B | -19.07B | -21.94B | -10.07B | -11.76B | -13.19B | -15.31B | -10.14B | -29.46B | -16.90B | -12.77B | -11.77B | -16.27B | -27.39B | -9.85B | -4.74B | -3.95B | -3.62B | -8.53B | -4.10B | -2.31B | -2.10B | -2.06B | -1.54B | -1.24B | -1.04B | -850.00M | -1.25B | -1.25B | -669.00M | -674.00M | -479.00M |
| Other Cash Details | |||||||||||||||||||||||||||||||||||
| End Cash Position | 21.86B | 14.13B | 14.49B | 13.99B | 17.31B | 18.11B | 17.82B | 18.97B | 13.73B | 14.52B | 20.93B | 14.91B | 24.54B | 19.36B | 15.81B | 10.77B | 7.77B | 4.08B | 16.06B | 9.20B | 5.38B | 2.89B | 3.76B | 4.28B | 2.51B | 1.99B | — | — | — | 636.00M | — | — | — | — | — |
| Income Tax Paid | 8.57B | 5.22B | 4.77B | 4.62B | 4.19B | 4.57B | 3.31B | 2.84B | -2.87B | 3.54B | 3.16B | 2.51B | 2.97B | 2.44B | 2.36B | 4.07B | 4.10B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 1.84B | 982.00M | 990.00M | 904.00M | 995.00M | 1.05B | 960.00M | 730.00M | -617.00M | 603.00M | 596.00M | 616.00M | 576.00M | 491.00M | 533.00M | 525.00M | 314.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 17.78B | 17.19B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B | 16.11B | 15.00B | 13.82B | 12.46B | 11.41B | 14.00B | 14.21B | 11.91B | 12.08B | 11.51B | 8.83B | 8.64B | 8.33B | 6.08B | 7.13B | 5.21B | 4.10B | 3.45B | 2.95B | 2.52B | 2.13B | 2.04B | 1.19B | 1.04B | 688.00M | 827.00M | 500.00M |
Error: Invalid format in Holders JSON file.
Article
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Feb 10, 2025
Article
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson. ("J&J" or the "Company") (NYSE:JNJ).
Feb 9, 2025
Article
2 Stocks to Buy if There Is a Market Crash in 2025
Equity markets have been volatile over the past week as some of the industry leaders in artificial intelligence (AI) -- which make up a large percentage of indexes like the Nasdaq Composite -- have been encountering stiff competition out of China.
Feb 9, 2025
